Bøger i Cancer Treatment and Research serien

Cancer Policy: Pharmaceutical Safety provides invaluable information on the interesting and compelling field of cancer drug safety.

This volume reviews and integrates the major advances in our understanding of the underlying molecular biology and pharmacology of hematopoietic growth factors in oncology. The results of well designed and executed randomized controlled trials are included.

- Provides the reader with insight into the emerging roles of the pathologist and clinical labortory- This volume includes all the latest concepts in the field

- National Cancer Institure Budget is encouraging research in order to develop a better understanding of metastasis of cancer to the bone- Provides the reader with comprehensive reviews written by well known experts on related topics

The underlying thesis in solid tumor biology is that metastasis in general starts in an orderly progression with lymphatic spread first to the sentinel lymph node (SLN) in the nearest lymph node basin.

Recent advances in radiation oncology have depended upon and are intertwined with subsequent scientific discoveries and the development of new techniques in the fields of radiation and molecular biology, physics, electrical engineering, surgery, and medical oncology.

This pertinently illustrated and well referenced text serves as an up-to-date, attractive book of oncologic imaging for radiologists, oncologists, radiation therapists and others involved in oncologic care.

This volume highlights many of the important advances that have improved our understanding of the biology and therapeutics of breast cancer. In addition to the well known genetic mutations BRCA1 and BRCA2, other mutations that have recently been identified are discussed.

Cancer Informatics in Post-Genomic Era provides both the necessary methodology and practical information tools for analyzing data in the field of medical information science.

One of the most important aspects of AIDS is the loss of protective immune function in the infected host which leads to increased prevalence of opportunistic infections and cancers. This book specifically addresses viral-induced human cancers associated with AIDS and observed in the AIDS population.

This book discusses emerging nanotechnology-based tools that have the potential to dramatically impact cancer research, diagnostics, and treatment. This book explains how nanotechnology can exploit the size-, shape-, and composition-dependent properties of nanomaterials to provide novel tools for precision cancer medicine.

- Provides the reader with insight into the emerging roles of the pathologist and clinical labortory- This volume includes all the latest concepts in the field

Brain metastases are the most dreaded complication of systemic cancer, affecting approximately 170,000 people a year, a far greater incidence than primary brain tumors. Advances in modern chemotherapy have led to an improved control of system cancers, often with agents that poorly penetrate the central nervous system, resulting in an increasing incidence of brain metastases. Traditional chemotherapy has had little impact on brain metastases. The main therapeutic option is radiation therapy, and in a small number of patients - surgery. However, refinements in all of these treatments offer some positive outcomes and an increased ability to stratify patients based on certain criteria.This book will bring current information on the presentation and management of patients with brain metastases, providing available data, giving guidelines that can be applied in day to day practice, updated information for neuro-surgeons, radiation oncologists, medical oncologists, and neuro-oncologists, as well as an overview for physicians in training.

In human solid cancer, the lymph node (LN) status is the most important prognostic indicator for the clinical outcome of patients. Recent developments in the sentinel lymph node (SLN) concept and technology have resulted in the application of this revolutionary approach to define the first draining or SLN to which the cancer may have metastasized. The underlying thesis in solid cancer biology is that metastasis generally starts in an orderly progression, spreading through the lymphatic channels to the SLN in the nearest LN basin. Thus, the logical approach is to harvest that specific SLN for thorough analysis. Because a tumorfree SLN is usually associated with a negative residual LN basin, a negative SLN is an excellent indication that micrometastasis has not occurred in the regional LNs. When the SLN is involved, it is unknown whether or not metastasis is limited only to the SLN or if the disease has spread to the remainder of the nodal basin. For this reason, if a SLN is positive, a complete lymph node dissection is recommended. Therefore, selective sentinel lymphadenectomy (SSL) should be considered as a staging procedure so that patients with negative SLNs (about 80%) may be spared an extensive LN dissection. Malignant melanoma has been proven to be the most ideal tumor model to study the role of SLN. Subsequently, SSL has been applied to breast cancer, colon cancer and other types of solid cancer. The multidisciplinary approach encompassing the surgeon, nuclear medicine physician, and pathologist is the key to such a successful procedure. Such a team can be formed readily with appropriate training. Beyond the technical aspects of harvesting the SLN, the implication of micrometastasis remains to be defined. Because the follow-up of melanoma and breast cancer patients after SSL is crucial, ongoing clinical trials are in progress to determine the biological and clinical significance of SLNs. Although the concept of SLN is viable in other types of cancer, such as gynecological and gastrointestinal, the technical aspects of the procedure need to be perfected and verified. The most exciting possibility of SSL is that it will lead to early diagnosis of micrometastasis in regional LNs. Early diagnosis makes it useful as a clinical staging procedure, and opens up new opportunities to study micrometastasis and its evolution within the SLNs. Examining the multifaceted aspects of micrometastasis, such as differentiation of different clones with respect to the primary tumor, acquisition of adhesion molecules, and host interaction with the microscopic tumor, will shed new light on the biology of early metastasis. New molecular and genetic tools may be used to dissect the mechanisms of lymphatic and hemo togenous routes of metastasis. If such mechanisms can be understood, new therapeutic advances may be developed to prevent the process of micrometastasis. Rather than targeting larger tumor burdens such as Stage IV disease, targeted adjuvant clinical trials can be developed for high risk patients following definit ive surgical resection. SSL is a standard staging procedure for patients with melanoma and is rapidly evolving into a standard procedure for breast cancer as well.

Accumulating evidence supports the role of defects in post-transcriptional gene regulation in the development of cancer. RNA and Cancer examines the recent advances in our understanding of post-transcriptional gene regulation, especially RNA processing and its role in cancer development and treatment.

This book reviews the significant advances in our understanding of glioma biology that have been achieved during the past decade and describes in detail the resultant new approaches to treatment. In addition, individual chapters are devoted specifically to current treatment for low-grade gliomas, anaplastic gliomas, and glioblastoma multiforme.

This book details the anatomy and physiology of the lymphovascular system as well as describes the mechanisms of metastasis. Coverage also explains the rationale of adopting molecular therapeutics against growth factor receptors, apoptotic factors, signaling pathways and angiogenesis.

In recent years a dramatic increase in knowledge of the biology of the lymphomas has been accompanied by the emergence of new treatments offering improvements in efficacy and reduction in toxicity.

Policy and outcome studies represent a new area of research in oncology. Understanding the factors that affect quality of life, costs of care, patterns of care, and outcomes in oncology is important to providing comprehensive care. In sum, Cancer Policy highlights some of the important areas of health services research in oncology.

Section One, `Diagnostic advances: the use of molecular medicine in the diagnosis and prognosis of GU malignancies', details how epidemiologic studies and new molecular techniques are impacting our ability to diagnose and treat GU tumors.

In recent years, there have been major advances in the treatment of patients with gynecologic malignancies. The advances made in the treatment of gynecologic malignancies are due, in part, to the clinical studies performed by many of the contributors to this volume.

In Breast Cancer: Cellular and Molecular Biology [Kluwer Academic Pub lishers, 1988], we tried to present an introduction to the emerging basic studies on steroid receptors, oncogenes, and growth factors in the regulation of normal and malignant mammary epithelium.

Gastric cancer has been one of the great malignant scourges affecting man kind for as long as medical records have been kept. Some changes have resulted from better understanding of the disease, early detec tion, and better management techniques with applied clinical research, but the reasons for other changes are poorly understood.

As a result, this multi-authored volume, devoted to advances which have occurred over the last seven years, provides the reader with an important new understanding of leukemia, but perhaps even more important, predicts analogous, new developments in the other malignant diagnoses.

Attempts to harness the inherent complexity of MDS by devising `classifications' which group the various syndromes as one disease is as misguided as saying that a pneumonia is not infectious because it did not respond to antibiotics.

Kidney cancer is a heterogenous disease. This book will be useful to the specialist (oncologist and urologist), primary care physicians, patients and family members dealing with kidney cancer.

It is an attempt to establish a critical mass of oncology literature covering virtually all oncology topics, revised frequently to keep the coverage up to date, easily available on a single library shelf or by a single personal subscription.

It is an attempt to establish a critical mass of oncology literature covering virtually all oncology topics, revised frequently to keep the coverage up to date, easily available on a single library shelf or by a single personal subscription.

It is an attempt to establish a critical mass of oncology literature covering virtually all oncology topics, revised frequently to keep the coverage up to date, easily available on a single library shelf or by a single personal subscription.